Repositioning Candidate Details
| Candidate ID: | R0220 |
| Source ID: | DB00621 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Oxandrolone |
| Synonyms: | -- |
| Molecular Formula: | C19H30O3 |
| SMILES: | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C |
| Structure: |
|
| DrugBank Description: | A synthetic hormone with anabolic and androgenic properties. |
| CAS Number: | 53-39-4 |
| Molecular Weight: | 306.4397 |
| DrugBank Indication: | Use to promote weight gain after weight loss following extensive surgery. |
| DrugBank Pharmacology: | Oxandrolone is an anabolic steroids indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis. Anabolic steroids are synthetic derivatives of testosterone. |
| DrugBank MoA: | Oxandrolones interact with androgen receptors in target tissues. |
| Targets: | Androgen receptor agonist |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |